BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 38579192)

  • 21. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
    Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
    ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment strategies for DNA repair-deficient prostate cancer.
    Teply BA; Antonarakis ES
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
    Das S; Cardin D
    Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
    Gonzalez D; Mateo J; Stenzinger A; Rojo F; Shiller M; Wyatt AW; Penault-Llorca F; Gomella LG; Eeles R; Bjartell A
    J Pathol Clin Res; 2021 Jul; 7(4):311-325. PubMed ID: 33630412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations.
    Park JJ; Chu A; Li J; Ali A; McKay RR; Hwang C; Labriola MK; Jang A; Kilari D; Mo G; Ravindranathan D; Graham LS; Sokolova A; Tripathi A; Pilling A; Jindal T; Ravindra A; Cackowski FC; Sweeney PL; Thapa B; Amery TS; Heath EI; Garje R; Zakharia Y; Koshkin VS; Bilen MA; Schweizer MT; Barata PC; Dorff TB; Cieslik M; Alva AS; Armstrong AJ
    JCO Precis Oncol; 2024 Apr; 8():e2300567. PubMed ID: 38579192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
    Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Genetics of Prostate Cancer and Role of Genomic Testing.
    Akhoundova D; Feng FY; Pritchard CC; Rubin MA
    Surg Pathol Clin; 2022 Dec; 15(4):617-628. PubMed ID: 36344179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
    Dhawan M; Ryan CJ
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    Cimadamore A; Cheng L; Massari F; Santoni M; Pepi L; Franzese C; Scarpelli M; Lopez-Beltran A; Galosi AB; Montironi R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.